• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

What to Know About Gene Therapy

by Fred Pennic 07/12/2022 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
What to Know About Gene Therapy

Gene therapy is making a world where cancer and AIDS can be cured, and a person can alter their genetic makeup, changing the direction of their own and their offspring’s evolution in the process. However, the effects of gene therapy are long-lasting, and may impact both your and the health of your future children. 

What Is Gene Therapy?

Utilizing a gene or genes to treat or cure a disease or medical condition is known as gene therapy. Gene therapy frequently involves replacing a damaged gene in a patient’s cells with a healthy copy or inserting new copies of a damaged gene. 

Instead of drugs or surgery, gene therapy procedures allow doctors to treat a problem by changing a person’s genetic composition. The first gene therapy technique, also known as gene transfer or gene addition, was created to:

– Add a new gene to cells to aid in treating a disease

– Introduce a healthy gene copy to replace the disease-causing altered copy

Later research helped to advance gene therapy methods. A more recent method, genome editing, takes a different tack in addressing genetic discrepancies. Genome editing uses molecular tools to alter the DNA already present in cells rather than introducing new genetic material. Research on genome editing aims to: 

– Restore a gene’s normal function

– Correct the genetic change that underlies an illness 

– Activate a gene that isn’t working correctly

– Eliminate a section of DNA that interferes with gene activity and causes illness

However, gene therapy is still a field that primarily exists in research labs, and its application is still being tested. The majority of trials take place in Europe, US, and Australia. The treatment is extensive and is being tested to be used to treat acquired genetic diseases like cancer and some viral infections like AIDS, as well as diseases brought on by recessive gene defects, including cystic fibrosis, hemophilia, muscular dystrophy, and sickle cell anemia.

Types of Gene Therapy

Gene therapy comes in various forms, including: 

– Gene editing: Gene editing aims to remove undesirable genes or fix mutated genes

– Cellular gene therapy: The patient’s cells are taken out, genetically altered (typically via a viral vector), and then put back in

– Plasmid DNA: It is possible to genetically modify circular DNA molecules to deliver healing genes into human cells

– Viral vectors: Certain gene therapy items are made from viruses because they naturally possess the potential to introduce genetic material into cells. These altered viruses can be employed as vectors to transport therapeutic genes into cells once viruses have been altered to reduce their capacity to spread infectious diseases 

Ethical Issues in Gene Therapy 

The idea of genetically altering genes has long been the subject of contentious debate in the scientific community. When new techniques are developed, bioethics is always present to evaluate the procedure’s hazards and moral ramifications. Genetic therapy in somatic cells is widely accepted in the scientific community, particularly in severe diseases like cystic fibrosis and Duchenne muscular dystrophy. 

For instance, the first experiment for modifying healthy human embryos was allowed in the United Kingdom. On the other hand, American research organizations remained conservative, restating their stance that they do not support this kind of trial and saying that they must wait for advancements in both the methods and the definitions of ethical issues.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: cancer, Coronavirus (COVID-19), dna, gene therapy

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

2026 Predictions & Trends

Healthcare 2026 Forecast: Executives on AI Survival, Financial Reckoning, and the End of Point Solutions

2026 Healthcare Executive Predictions: Why the AI “Pilot Era” Is Officially Over

Most-Read

HHS Launches 'OneHHS' AI Strategy to Integrate AI Across CDC, CMS, and FDA for Efficiency and Public Trust

HHS Launches ‘OneHHS’ AI Strategy to Integrate AI Across CDC, CMS, and FDA for Efficiency and Public Trust

Kristen Hartsell, VP of Clinical Services, RedSail Technologies

The Pharmacy Closures Crisis: How Independent Pharmacies Are Fixing Pharmacy Deserts

From Overwhelmed to Optimized: How AI Agents Address Staffing Challenges and Burnout in Healthcare

From Overwhelmed to Optimized: How AI Agents Address Staffing Challenges and Burnout in Healthcare

The VBC Paradox: Why Hospitals Are Doubling Down on Value-Based Care While Revenue at Risk Lags

The VBC Paradox: Why Hospitals Are Doubling Down on Value-Based Care While Revenue at Risk Lags

Tebra Secures $250M to Challenge Legacy EHRs with AI-Powered Automation

Tebra Secures $250M to Challenge Legacy EHRs with AI-Powered Automation

AstraZeneca Selects Salesforce Agentforce Life Sciences to Deploy AI-Powered Global Customer Engagement

AstraZeneca Selects Salesforce Agentforce Life Sciences to Deploy AI-Powered Global Customer Engagement

Aidoc Partners with NVIDIA MONAI to Scale Open-Source Clinical AI

Aidoc Partners with NVIDIA MONAI to Scale Open-Source Clinical AI

RapidAI Secures FDA Clearance for Five New Deep Clinical AI Modules, Expanding Enterprise Imaging Platform

RapidAI and AWS Deepen Partnership to Scale Clinical AI in Healthcare

Greece and Sword Health to Build AI-Powered Healthcare Front Door

Greece and Sword Health to Build AI-Powered Healthcare Front Door

GE HealthCare Acquires Intelerad for $2.3B to Create Cloud-First, AI-Enabled Imaging Ecosystem

GE HealthCare Acquires Intelerad for $2.3B to Create Cloud-First, AI-Enabled Imaging Ecosystem

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |